298PEFFICACY OF ADJUVANT 9-WEEKS TRASTUZUMAB IN NODE-NEGATIVE T1A/B HER2-POSITIVE BREAST CANCER

Abstract Aim: The benefit of the addition of 9-weeks or 52-weeks adjuvant trastuzumab to chemotherapy compared with chemotherapy alone was shown in five randomized trials. Despite retrospective series having shown the poor prognosis of HER2-positive T1a/b node-negative tumors, the efficacy of adjuva...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of oncology 2014-09, Vol.25 (suppl_4), p.iv100-iv100
Hauptverfasser:	Sendur, M.A., Aksoy, S., Uncu, D., Demir, H., Yuksel, S., Ekinci, A.S., Kaplan, M.A., Ustaalioglu, B.B., Tufan, G., İnanc, M., Ozdemir, N., Artac, M., Taştekin, D., Kacan, T., Oguz, A., Arpaci, E., Yazılıtas, D., Gumus, M., Zengin, N., Altundag, M.K.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!